Jennifer Schneiderman

List of Publications by Year
in descending order

34 papers	1,815 citations	623574 14 h-index	414303 32 g-index
34 all docs	34 docs citations	34 times ranked	2485 citing authors

#	Article	IF	Citations
1	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€“ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 2019, 34, 171-354.	0.7	1,263
2	Betibeglogene Autotemcel Gene Therapy for Nonâ€“Î² ⁰ /Î² ⁰ Genotype Î²-Thalassemia. New England Journal of Medicine, 2022, 386, 415-427.	13.9	91
3	Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 913-918.	0.8	67
4	Secondary malignant neoplasms after highâ€dose chemotherapy and autologous stem cell rescue for highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2014, 61, 1350-1356.	0.8	40
5	Report of the <scp>ASFA</scp> apheresis registry study on Wilson's disease. Journal of Clinical Apheresis, 2016, 31, 11-15.	0.7	35
6	National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis. Transfusion Medicine Reviews, 2015, 29, 62-70.	0.9	31
7	The use of fluid boluses to safely perform extracorporeal photopheresis (ECP) in lowâ€weight children: A novel procedure. Journal of Clinical Apheresis, 2010, 25, 63-69.	0.7	29
8	Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. Journal of Clinical Apheresis, 2017, 32, 215-223.	0.7	27
9	American council on ECP (ACE): Why now?. Journal of Clinical Apheresis, 2018, 33, 464-468.	0.7	26
10	Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants. Journal of Pediatric Hematology/Oncology, 2018, 40, 31-35.	0.3	26
11	Update to the <scp>ASFA</scp> guidelines on the use of therapeutic apheresis in <scp>ANCAâ€associated</scp> vasculitis. Journal of Clinical Apheresis, 2020, 35, 493-499.	0.7	24
12	Correction of enzyme levels with allogeneic hematopoeitic progenitor cell transplantation in Niemannâ€Pick type B. Pediatric Blood and Cancer, 2007, 49, 987-989.	0.8	23
13	An international survey of pediatric apheresis practice. Journal of Clinical Apheresis, 2014, 29, 120-126.	0.7	22
14	Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease. Hematology American Society of Hematology Education Program, 2017, 2017, 639-644.	0.9	15
15	Extracorporeal photopheresis in pediatric patients: Practical and technical considerations. Journal of Clinical Apheresis, 2017, 32, 543-552.	0.7	14
16	Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: Improved outcomes for de novo disease. Pediatric Transplantation, 2011, 15, 334-343.	0.5	11
17	Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1612-1621.	2.0	11
18	The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients. Journal of Pediatric Hematology/Oncology, 2017, 39, 26-32.	0.3	11

#	Article	IF	Citations
19	Early mixed Tâ€cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2017, 64, e26493.	0.8	7
20	Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation. Current Pharmaceutical Design, 2008, 14, 1987-1996.	0.9	5
21	Use of allogeneic stem cell transplantation for moderateâ€“severe Glanzmann thrombasthenia. Platelets, 2015, 26, 702-704.	1.1	5
22	Lack of defined apheresis collection criteria in publicly available <scp>CARâ€T</scp> cell clinical trial descriptions: Comprehensive review of over 600 studies. Journal of Clinical Apheresis, 2022, 37, 223-236.	0.7	5
23	Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 169-174.	0.6	4
24	Reducedâ€toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for highâ€risk hematologic malignancies. Pediatric Blood and Cancer, 2021, 68, e29087.	0.8	4
25	Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models. Scientific Reports, 2022, 12, 7298.	1.6	4
26	Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy. Leukemia and Lymphoma, 2016, 57, 949-952.	0.6	3
27	Diagnostic Utility of Complement Immunohistochemical Studies in Postâ€“Stem Cell Transplant Intestinal Thrombotic Microangiopathy: Case Report. Journal of Pediatric Hematology/Oncology, 2017, 39, 282-286.	0.3	3
28	High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes. Pediatric Hematology and Oncology, 2018, 35, 316-321.	0.3	3
29	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for preâ€transplant minimal residual disease reduction. Pediatric Blood and Cancer, 2021, 68, e28574.	0.8	2
30	A Novel Mutation in WAS Gene Causing a Phenotypic Presentation of Wiskott-Aldrich Syndrome: A Case Report. Journal of Pediatric Hematology/Oncology, 2021, 43, e234-e236.	0.3	2
31	Reduced Intensity Conditioning (RIC) and Hematopoietic Stem Cell Transpalntation (HSCT) Utilizing Extracorporeal Photopheresis (ECP), Fludarabine, and Targeted Dose Busulfan in Children.. Blood, 2006, 108, 5307-5307.	0.6	1
32	Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis. Cytotherapy, 2022, , .	0.3	1
33	Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.. Blood, 2009, 114, 1780-1780.	0.6	0
34	Robust Immune Reconstitution in Children with Severe Primary Immunodeficiency after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3923-3923.	0.6	0